Distribution of Nitroimidazoles and L-phenylalanine Mustard in Mammary Adenocarcinoma 16/C Tumors

Overview

Journal Cancer Chemother Pharmacol

Specialty Oncology

Date 1987 Jan 1

PMID 3677296

Authors

P E Noker

L Simpson-Herren

S D Wagoner

Affiliations

Soon will be listed here.

Abstract

Using the triphenylmethane dye, lissamine green, as an indicator of blood perfusion, we have demonstrated that L-phenylalanine mustard (L-PAM) is differentially distributed in mice bearing mammary adenocarcinoma 16/C tumors. Following i.p. administration, concentrations of L-PAM in various regions of the tumors vary by as much as 10-fold or more between regions of low and high perfusion. Since the nitroimidazoles, metronidazole and misonidazole, increase the cytotoxicity of certain antitumor agents, these compounds were investigated for their ability to increase the distribution of L-PAM into tumor regions of low perfusion. Administration of metronidazole (400 mg/kg) or misonidazole (800 mg/kg) 1 h prior to L-PAM and lissamine green resulted in elevated plasma levels of L-PAM and increased concentrations of L-PAM in tumor regions of high perfusion. A slight increase in the normally low levels of L-PAM in tumor regions of low perfusion was observed but the increase was not statistically significant. In contrast to the uneven distribution of L-PAM, metronidazole and misonidazole were evenly distributed throughout plasma and tumor regions of both high and low perfusion. Bioassay of tumors following in vivo exposure to metronidazole and L-PAM indicated decreased viability in fragments from tumor regions of high perfusion, but not from tumor regions of low perfusion. These studies demonstrate that the nitroimidazoles increased L-PAM levels in plasma and in tumor regions of both high and low perfusion but did not induce a uniform distribution of L-PAM throughout the tumors. The nitroimidazoles may enhance the effectiveness of L-PAM as an antitumor agent by increasing the concentration of drug that reaches a tumor.

References

Ash D, Smith M, Bugden R . Distribution of misonidazole in human tumours and normal tissues. Br J Cancer. 1979; 39(5):503-9. PMC: 2009904. DOI: 10.1038/bjc.1979.93. View

Randhawa V, Stewart F, Denekamp J, Stratford M . Factors influencing the chemosensitization of melphalan by misonidazole. Br J Cancer. 1985; 51(2):219-28. PMC: 1977037. DOI: 10.1038/bjc.1985.32. View

Chirigos M, MEAD J . EXPERIMENTS ON DETERMINATION OF MELPHALAN BY FLUORESCENCE. INTERACTION WITH PROTEIN AND VARIOUS SOLUTIONS. Anal Biochem. 1964; 7:259-68. DOI: 10.1016/0003-2697(64)90130-7. View

Foster J, Conroy P, Searle A, Willson R . Metronidazole (Flagyl): characterization as a cytotoxic drug specific for hypoxic tumour cells. Br J Cancer. 1976; 33(5):485-90. PMC: 2024956. DOI: 10.1038/bjc.1976.78. View

Simpson-Herren L, Noker P, Wagoner S . Variability of tumor response to chemotherapy. II. Contribution of tumor heterogeneity. Cancer Chemother Pharmacol. 1988; 22(2):131-6. DOI: 10.1007/BF00257310. View

Blasberg R, Horowitz M, Strong J, Molnar P, Patlak C, Owens E . Regional measurements of [14C]misonidazole distribution and blood flow in subcutaneous RT-9 experimental tumors. Cancer Res. 1985; 45(4):1692-701. View

Evans T, Chang S, Alberts D, Sipes I, Brendel K . In vitro degradation of L-phenylalanine mustard (L-PAM). Cancer Chemother Pharmacol. 1982; 8(2):175-8. DOI: 10.1007/BF00255479. View

Harrison Jr S, Giles H, Denine E . Antitumor drug toxicity in tumor-free and tumor-bearing mice. Cancer Chemother Pharmacol. 1980; 4(3):199-204. DOI: 10.1007/BF00254019. View

Hirst D, Brown J, HAZLEHURST J . Enhancement of CCNU cytotoxicity by misonidazole: possible therapeutic gain. Br J Cancer. 1982; 46(1):109-16. PMC: 2011076. DOI: 10.1038/bjc.1982.172. View

10.

Furner R, Brown R . L-phenylalanine mustard (L-PAM): the first 25 years. Cancer Treat Rep. 1980; 64(4-5):559-74. View

11.

Schwartz D, JEUNET F . Comparative pharmacokinetic studies of ornidazole and metronidazole in man. Chemotherapy. 1976; 22(1):19-29. DOI: 10.1159/000221906. View

12.

Simpson-Herren L, Noker P, Wagoner S . Variability of tumor response to chemotherapy. I. Contribution of host heterogeneity. Cancer Chemother Pharmacol. 1987; 20(4):297-304. DOI: 10.1007/BF00262580. View

13.

Furner R, MELLETT L, Brown R, Duncan G . A method for the measurement of L-phenylalanine mustard in the mouse and dog by high-pressure liquid chromatography. Drug Metab Dispos. 1976; 4(6):577-83. View

14.

McNally N, Hinchliffe M, De Ronde J . Enhancement of the action of alkylating agents by single high, or chronic low doses of misonidazole. Br J Cancer. 1983; 48(2):271-8. PMC: 2011437. DOI: 10.1038/bjc.1983.182. View

15.

Stambaugh J, FEO L, Manthei R . The isolation and identification of the urinary oxidative metabolites of metronidazole in man. J Pharmacol Exp Ther. 1968; 161(2):373-81. View

16.

Workman P . Pharmacokinetics of hypoxic cell radiosensitizers: a review. Cancer Clin Trials. 1980; 3(3):237-51. View

17.

Hinchliffe M, McNally N, Stratford M . The effect of radiosensitizers on the pharmacokinetics of melphalan and cyclophosphamide in the mouse. Br J Cancer. 1983; 48(3):375-83. PMC: 2011478. DOI: 10.1038/bjc.1983.202. View

18.

Workman P, Little C, Marten T, DALE A, Ruane R, Flockhart I . Estimation of the hypoxic cell-sensitiser misonidazole and its O-demethylated metabolite in biological materials by reversed-phase high-performance liquid chromatography. J Chromatogr. 1978; 145(3):507-12. DOI: 10.1016/s0378-4347(00)81386-9. View

19.

Smith E, Stratford I, Adams G . Enhancing effect of pre-treatment of cells with misonidazole in hypoxia on their response to melphalan in air. Br J Cancer. 1982; 46(1):117-26. PMC: 2011057. DOI: 10.1038/bjc.1982.173. View

20.

Tannock I . In vivo interaction of anti-cancer drugs with misonidazole or metronidazole: cyclophosphamide and BCNU. Br J Cancer. 1980; 42(6):871-80. PMC: 2010569. DOI: 10.1038/bjc.1980.335. View